scholarly journals Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial

2012 ◽  
Vol 109 (10) ◽  
pp. 1856-1865 ◽  
Author(s):  
Shoji Shinkai ◽  
Masamichi Toba ◽  
Takao Saito ◽  
Ikutaro Sato ◽  
Mina Tsubouchi ◽  
...  
Keyword(s):  
Common Cold ◽  
Low Dose ◽  
Controlled Trial ◽  
Oral Intake ◽  
High Dose ◽  
Elderly Adults ◽  
Double Blind ◽  
Lactobacillus Pentosus ◽  
Sf 36 ◽  
The Common

Oral intake of Lactobacillus pentosus strain b240 (b240) has been shown to enhance the secretion of salivary secretory IgA in elderly adults. However, its clinical benefits remain to be determined. We tested the hypothesis that b240 exerts a protective effect against the common cold in elderly adults. The design of the present study was a randomised, double-blind, placebo-controlled trial (RCT) with parallel three-group comparison. For this purpose, 300 eligible elderly adults were randomly allocated to one of three groups, namely a placebo, low-dose or high-dose b240 group. Participants in the low-dose and high-dose b240 groups were given tablets containing 2 × 109 or 2 × 1010 cells, respectively, of heat-killed b240, while those in the placebo group were given tablets without b240. Each group consumed their respective tablets once daily for 20 weeks. The common cold was assessed on the basis of a diary. Change in quality of life was evaluated using the SF-36®. Of the total participants, 280 completed the 20-week RCT. The accumulated incidence rate of the common cold was 47·3, 34·8 and 29·0 % for the placebo, low-dose b240 and high-dose b240 groups, respectively (P for trend = 0·012). Lower incidence rates were consistently observed throughout the experimental period in the b240 groups (log-rank test, P= 0·034). General health perception, as determined by the SF-36®, dose-dependently increased in the b240 groups (P for trend = 0·016). In conclusion, oral intake of b240 significantly reduced the incidence rate of the common cold in elderly adults, indicating that b240 might be useful in improving resistance against infection through mucosal immunity.

scholarly journals Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Ralf Uebelhack ◽  
Udo Bongartz ◽  
Stephanie Seibt ◽  
Gordana Bothe ◽  
Pee Win Chong ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Placebo Group ◽  
Body Fat ◽  
Dose Group ◽  
Low Dose ◽  
Clinical Investigation ◽  
Controlled Trial ◽  
High Dose ◽  
Double Blind

Objective. This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in overweight to moderately obese adults. Methods. A double-blind, randomized, placebo-controlled trial involved one hundred and eight subjects (BMI between 25 and 35 kg/m2) that were randomly assigned to either the low-dose or the high-dose IQP-AE-103 group, or the placebo group. Following a 2-week run-in period, subjects received two capsules of investigational product after three daily main meals for 12 weeks. Subjects were instructed to maintain a nutritionally balanced hypocaloric diet according to the individual’s energy requirement. Body weight, body fat, and waist and hip circumference were measured at baseline, and after 2, 4, 8, and 12 weeks. Subjects also rated their feelings of hunger and fullness using visual analogue scales, and food craving on a 5-point scale at the same time intervals. Blood samplings for safety laboratory parameters were taken before and at the end of the study. Results. After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the placebo (5.03 ± 2.50 kg vs. 0.98 ± 2.06 kg, respectively; p<0.001) and the low-dose group (3.01 ± 2.19 kg; p=0.001). The high-dose group experienced a decrease in body fat of 3.15 ± 2.41 kg compared with a decrease of 0.23 ± 2.74 kg for the placebo group (p<0.001). High-dose IQP-AE-103 also decreased the feeling of hunger in 66% subjects. A beneficial effect of IQP-AE-103 on the lipid metabolism was also demonstrated in the subgroup of subjects with baseline total cholesterol levels above 6.2 mmol/L. No side effects related to the intake of IQP-AE-103 were reported. Conclusions. These findings indicate that IQP-AE-103 could be an effective and safe weight loss intervention. This trial is registered with NCT03058367.

scholarly journals A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0122330 ◽  
Author(s):  
Toshio Watanabe ◽  
Toshihisa Takeuchi ◽  
Osamu Handa ◽  
Yasuhisa Sakata ◽  
Tetsuya Tanigawa ◽  
...  
Keyword(s):  
Low Dose ◽  
Controlled Trial ◽  
High Dose ◽  
Intestinal Damage ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Small Intestinal

scholarly journals Effects of -Cystine and -Theanine Supplementation on the Common Cold: A Randomized, Double-Blind, and Placebo-Controlled Trial

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Shigekazu Kurihara ◽  
Takenori Hiraoka ◽  
Masahisa Akutsu ◽  
Eiji Sukegawa ◽  
Makoto Bannai ◽  
...  
Keyword(s):  
Common Cold ◽  
Controlled Trial ◽  
Double Blind ◽  
The Common

Effects of So-cheong-ryong-tang and Yeon-gyo-pae-dok-san on the common cold: Randomized, double blind, placebo controlled trial

2011 ◽  
Vol 133 (2) ◽  
pp. 642-646 ◽  
Author(s):  
Jun-Seop Byun ◽  
Su-Young Yang ◽  
In-Cheol Jeong ◽  
Kwon-Eui Hong ◽  
Weechang Kang ◽  
...  
Keyword(s):  
Common Cold ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
The Common
Sign in / Sign up

Export Citation Format

Share Document